MARKET

CELG-RT

CELG-RT

Celgene
NYSE

Real-time Quotes | Nasdaq Last Sale

0.4800
-0.0100
-2.04%
Closed 16:00 06/05 EDT
OPEN
0.4988
PREV CLOSE
0.4900
HIGH
0.4997
LOW
0.4600
VOLUME
18.11K
TURNOVER
--
52 WEEK HIGH
1.240
52 WEEK LOW
0.2711
MARKET CAP
341.47M
P/E (TTM)
0.0599
1D
5D
1M
3M
1Y
5Y

CELG-RT News

More
Bristol-Myers Placed A Big Bet On Celgene�s Pipeline. Will It Pay Off For Investors?
MotleyFool.com · 12/16/2019 14:55
Better Buy: Gilead Sciences vs. Amgen
MotleyFool.com · 12/15/2019 14:00
Here's Why You Should Own Amgen Stock in 2020
MotleyFool.com · 12/12/2019 15:38
Here�s Why bluebird bio Shares Jumped Almost 12% Today
MotleyFool.com · 12/10/2019 21:31
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both
MotleyFool.com · 12/10/2019 20:54
Better Buy: Biogen vs. Amgen
MotleyFool.com · 12/08/2019 19:00
Better Buy: Pfizer vs. Bristol-Myers Squibb
MotleyFool.com · 12/08/2019 12:00
Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price
MotleyFool.com · 12/07/2019 13:00

Industry

Pharmaceuticals
+0.57%
Pharmaceuticals & Medical Research
+0.37%

Hot Stocks

Symbol
Price
%Change

About CELG-RT

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
More

Webull offers kinds of Celgene Corporation stock information, including NYSE:CELG RT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG RT stock news, and many more online research tools to help you make informed decisions.